CG CHONDROGENE Logo (USPTO, 12/31/2003)
USPTOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The US trademark CG CHONDROGENE was filed as Word and figurative mark on 12/31/2003 at the U.S. Patent and Trademark Office.
It was registered as a trademark on 07/21/2009.
The current status of the mark is "CANCELLED - SECTION 8".
| Trademark form | Word and figurative mark |
| File reference | 76568022 |
| Register number | 3656206 |
| Application date | December 31, 2003 |
| Publication date | October 7, 2008 |
| Entry date | July 21, 2009 |
Trademark owner
2 East Beaver Creek Road, Bldg 2
Ontario L Richmond Hill
CA
Ontario L Richmond Hill
CA
Trademark representatives
goods and services
1
(Based on Use in Commerce) (Based on 44(e)) Diagnostic preparations, namely, preparations of extracts and nucleic acids, namely, RNA and cDNA clones for medical research and development use; (Based on on 44(e)) Diagnostic assays and test kits for use in laboratory, medical research and chemical research and development; Diagnostic assays and test kits containing nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies and molecular arrays of biological material, for use to diagnose, prognoses or predict diseases for research use; Prognostic test kits containing nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies and molecular arrays of biological material, for identifying disease risk factors and responses to therapeutic treatment for research use
5
(Based on 44(e)) Diagnostic preparations, namely, preparations of assays, nucleic acid primers, nucleic acid probes, proteins and antibodies, and molecular arrays of biological material for medical laboratory use; Diagnostic assays and test kits containing nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies and molecular arrays of biological material, for use to diagnose, prognoses or predict diseases for clinical or medical use; Prognostic test kits containing nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies and molecular arrays of biological material, for identifying disease risk factors and responses to therapeutic treatment for clinical or medical use; diagnostic preparations, namely, preparations of assays, nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies, and molecular arrays of biological material for clinical or medical use; diagnostic preparations, namely, preparations of extracts and nucleic acids, namely, RNA and cDNA clones for clinical use
42
(Based on Use in Commerce) (Based on 44(e)) Research and development, validation testing, data analysis and product development in the fields of biology, systems biology, biochemistry, molecular biology and genomics; (Based on 44(e)) Research and development, validation testing, data analysis and product development in the fields of pharmacogenomics, toxicogenomics and personalized medicine; Evaluation of clinical trial progress, and drug monitoring and monitoring of patient health progression as it relates to experimental research
44
(Based on 44(e)) Diagnostic services, namely, diagnosing, preventing and predicting disease, identifying disease risk factors, diagnostic testing, gene and protein testing, identifying physiological characteristics, establishing individual preventative care programs, establishing disease treatment based on gene and protein expression and/or activity; providing genomic, proteomic and gene expression profiles useful in selecting therapeutics, evaluating the efficacy and toxicity of treatments and evaluating treatment progression, prognosing disease or disease progression and identifying disease heredity risk factors
ID: 1376568022